Enliven Therapeutics Statistics
Want to see ELVN full AI Analyst Report?
Enliven Therapeutics (ELVN) Stock Statistics & Valuation Metrics
Total Valuation
Enliven Therapeutics has a market cap or net worth of $3.77B. The enterprise value is $2.69B.
- Market Cap
- $3.77B
- Enterprise Value
- $2.69B
Share Statistics
Enliven Therapeutics has 73,595,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 73,595,130
- Owned by Insiders
- 22.42%
- Owned by Institutions
- 39.09%
Financial Efficiency
Enliven Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -26.01%.
- Return on Equity (ROE)
- -0.23
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -26.01%
- Return on Capital Employed (ROCE)
- -0.26
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.60M
- Employee Count
- 65
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Enliven Therapeutics is -30.47. Enliven Therapeutics’s PEG ratio is -3.68.
- PE Ratio
- -30.47
- PS Ratio
- 0.00
- PB Ratio
- 4.55
- Price to FCF
- -56.73
- Price to Operating Cash Flow
- -60.29
- PEG Ratio
- -3.68
Income Statement
In the last 12 months, Enliven Therapeutics had revenue of 0 and earned -103.69M in profits. Earnings per share was -1.83.
- Revenue
- 0
- Gross Profit
- -263.00K
- Operating Income
- -119.66M
- Pretax Income
- -103.69M
- Net Income
- -103.69M
- EBITDA
- -103.43M
- Earnings Per Share (EPS)
- -1.83
Cash Flow
In the last 12 months, operating cash flow was -66.22M and capital expenditures -193,000, giving a free cash flow of -66.41M billion.
- Operating Cash Flow
- -66.22M
- Free Cash Flow
- -66.41M
- Free Cash Flow per Share
- -0.85
Dividends & Yields
Enliven Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.75%
- Earnings Yield
- -2.83%
Stock Price Statistics
- Beta
- 0.78
- 52-Week Price Change
- 160.64%
- 50-Day Moving Average
- 47.28
- 200-Day Moving Average
- 43.58
- Relative Strength Index (RSI)
- 66.41
- Average Volume (3m)
- 1.34M
Important Dates
Enliven Therapeutics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Enliven Therapeutics as a current ratio of 28.66, with Debt / Equity ratio of 0.09%
- Current Ratio
- 28.66
- Quick Ratio
- 28.66
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.95
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Enliven Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Enliven Therapeutics EV to EBITDA ratio is -32.10, with an EV/FCF ratio of -54.82.
- EV to Sales
- 0.00
- EV to EBITDA
- -32.10
- EV to Free Cash Flow
- -54.82
- EV to Operating Cash Flow
- -54.98
Balance Sheet
Enliven Therapeutics has $884.35M in cash and marketable securities with $1.31M in debt, giving a net cash position of $883.04M billion.
- Cash & Marketable Securities
- $884.35M
- Total Debt
- $1.31M
- Net Cash
- $883.04M
- Net Cash Per Share
- $12.00
- Tangible Book Value Per Share
- $11.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Enliven Therapeutics is $74.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $74.88
- Price Target Upside
- 46.27% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 7.94%
Scores
- Smart Score
- 9
- AI Score
- 52
